Skip to main content
. Author manuscript; available in PMC: 2012 May 27.
Published in final edited form as: Dev Biol. 2011 Jul 23;358(1):102–112. doi: 10.1016/j.ydbio.2011.07.015

Fig. 2. Myogenin cooperates with Myod in fast myogenesis.

Fig. 2

A. Schematic of Myog gene and protein showing the fh265 glutamine to stop mutation following the helix-loop-helix domain. B-E. In situ mRNA hybridization for myog (B) or myhz1 (E) or immunodetection of Myog and slow MyHC (C) or MyHC (D) in myog+/fh265 incrosses, injected with myod morpholino as indicated (E). B. Expression of myog mRNA is little affected in myogfh265 mutants. Dorsal flatmounts, anterior to top. C. Nuclear immunoreactivity with a polyclonal anti-rat Myog antibody is lost in myogfh265 mutants at 22s. D. All embryos from a myog+/fh265 incross show normal levels of MyHC at 4 dpf. E. No change in myhz1 mRNA is detected in myogfh265 mutants at 24 hpf (top panel). Injection of myod MO into myogfh265 (bottom panel) leads to a greater loss of fast muscle than when injected into their siblings (middle panel), which are comparable to myodfh261 mutants (see Fig. 1F). Lateral views, anterior to left (C-E). Bars = 100 μm (except C = 20 μm).